World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of hepatocellular carcinoma (HCC). In order to assess the relative contribution of HBV and HCV to HCC worldwide, and identify changes over time, we conducted a systematic review of case series published up to the year 2014. Eligible studies had to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti‐HCV), alone and in combination, for at least 20 adult HCC cases. Studies using a first‐generation enzyme‐linked immunosorbent assay test for HCV were excluded. A total of 119,000 HCC cases in 260 studies were included from 50 countries. Most European and American countries show a preponderance of HCV over HBV and a substantial fraction of viral marker–negative cases. Asian and African countries generally show a predominance of HBV. The fraction of HCV‐positive HCC cases is substantial in Taiwan, Mongolia, Japan, and Pakistan as well as in Western‐Central Asia and Northern Africa. No eligible studies were available in Oceania, large parts of Africa, Eastern Europe, and Central Asia. The United States, Brazil, and Germany show evidence of higher prevalence of HCV in HCC since the year 2000. Conversely, Japan and Italy show a decline in the proportion of HCV‐positive HCC. Conclusion: HBV and HCV are predominant causes of HCC in virtually all world areas, with a growing fraction of HCC cases in several countries attributable to HCV. (Hepatology 2015;62:1190‐1200)

[1]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[2]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[3]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[4]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[5]  Mohsen Naghavi,et al.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis , 2014, BMC Medicine.

[6]  Jun Yu,et al.  Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. , 2014, World journal of gastroenterology.

[7]  L. Roberts,et al.  Treating hepatitis C in lower-income countries. , 2014, The New England journal of medicine.

[8]  M. Hellard,et al.  Interferon-free hepatitis C treatment: one pill to fit all? , 2014, The Lancet.

[9]  S. Thorgeirsson,et al.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. , 2013, Carcinogenesis.

[10]  Aijaz Ahmed,et al.  Both HCV and HBV are Major Causes of Liver Cancer in Southeast Asians , 2013, Journal of Immigrant and Minority Health.

[11]  M. Salminen,et al.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.

[12]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[13]  K. Malik,et al.  Human Development Report 2013. The Rise of the South: Human Progress in a Diverse World , 2013 .

[14]  M. Buti,et al.  Predicted effects of treatment for HCV infection vary among European countries. , 2012, Gastroenterology.

[15]  Rebecca L Morgan,et al.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. , 2012, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[16]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[17]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[18]  B. Graubard,et al.  Risk of liver cancer among US male veterans with cirrhosis, 1969–1996 , 2012, British Journal of Cancer.

[19]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[20]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[21]  Wei Wu,et al.  Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta‐analysis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[22]  I. Hung,et al.  Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma , 2011, Hepatology.

[23]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[24]  Ning Wang,et al.  Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis , 2011, BMC infectious diseases.

[25]  C. Wild,et al.  A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. , 2009, Cancer letters.

[26]  J. Kaldor,et al.  Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study , 2007, Australian and New Zealand journal of public health.

[27]  S. Franceschi,et al.  Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review , 2007, British Journal of Cancer.

[28]  C. la Vecchia,et al.  Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy , 2006, Cancer Epidemiology Biomarkers & Prevention.

[29]  S. Mano,et al.  Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. , 2006, Gastroenterology.

[30]  S. Lai,et al.  Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. , 2005, The Journal of infectious diseases.

[31]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[32]  K. McGlynn,et al.  The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update , 2003, Annals of Internal Medicine.

[33]  S. Richter Laboratory Assays for Diagnosis and Management of Hepatitis C Virus Infection , 2002, Journal of Clinical Microbiology.

[34]  J. Neuberger,et al.  Clinical guidelines on the management of hepatitis C , 2001, Gut.

[35]  M. Tattersall,et al.  Hepatocellular carcinoma in central Sydney:a 10-year review of patients seen in a medical oncology department. , 1999, World journal of gastroenterology.

[36]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[37]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[38]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[39]  T. Therneau,et al.  Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. , 2012, Mayo Clinic proceedings.

[40]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[41]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.